12:00 AM
 | 
Jun 03, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Kyprolis carfilzomib: Phase I data

An open-label, U.S. Phase I trial in 17 patients with relapsed or refractory CLL or small lymphocytic leukemia (SLL) showed that there were no DLTs with twice-weekly IV carfilzomib up to the highest tested dose of 56 mg/m 2. The MTD has not yet been reached. Grade 3/4 adverse events included neutropenia, febrile neutropenia and thrombocytopenia. The median number of cycles received was 3, with 9 cases of stable disease observed after...

Read the full 340 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >